Dr. Schlechter is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
450 Brookline Ave
Boston, MA 02215Phone+1 857-215-0430
Education & Training
Beth Israel Deaconess Medical CenterFellowship, Hematology and Medical Oncology, 2011 - 2014- Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 2008 - 2011
Tel Aviv University SacklerClass of 2008
Certifications & Licensure
MA State Medical License 2012 - 2025
Clinical Trials
- Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer Start of enrollment: 2019 Apr 01
Roles: Principal Investigator, Contact
Publications & Presentations
PubMed
- 41 citationsOrganoid Sensitivity Correlates with Therapeutic Response in Patients with Pancreatic Cancer.Joseph E. Grossman, Lakshmi Muthuswamy, Ling Huang, Dipikaa Akshinthala, Sofia Perea
Clinical Cancer Research. 2021-11-17 - 6 citationsBotensilimab plus balstilimab in relapsed/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trial.Andrea J Bullock, Benjamin L Schlechter, Marwan G Fakih, Apostolia M Tsimberidou, Joseph E Grossman
Nature Medicine. 2024-09-01 - 1 citationsCCR5 and CCL5 in metastatic colorectal cancer.Benjamin L Schlechter, Justin Stebbing
Journal for Immunotherapy of Cancer. 2024-05-07
Press Mentions
Adjuvant Chemo in Colorectal Cancer: What's Working Now?August 6th, 2024- Researchers Report First Effective Use of Immunotherapy for Most Common Subtype of Colorectal CancerJune 25th, 2024
- Young-Onset Colorectal Cancer: How Do We Move Forward?May 1st, 2024
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
